Drug Res (Stuttg) 2016; 66(05): 275-278
DOI: 10.1055/s-0035-1569296
Short Communication
© Georg Thieme Verlag KG Stuttgart · New York

Compounded Formulations of Dimethyl Fumarate Show Significant Variability in Product Characteristics

P. Boulas
1  Biogen, Cambridge, MA, USA
› Author Affiliations
Further Information

Publication History

received 23 July 2015

accepted 25 November 2015

Publication Date:
23 December 2015 (online)

Abstract

Background: Pharmacy compounded products are not regulated to the same standards as commercially available, approved products, increasing potential safety and efficacy risks to patients. This report describes an in vitro study examining consistency of content and release profile of compounded dimethyl fumarates.

Methods: Samples of compounded dimethyl fumarate (cDMF-A, cDMF-B, cFumaderm) from separate Austrian compounding pharmacies were analyzed for drug content, uniformity of dosage, impurity, and in vitro release.

Results: The average dimethyl fumarate (DMF) content ranged from 102.5 to 96.7% of the 120 mg content listed on the product labels. While the DMF capsule-to-capsule content of cDMF-A was somewhat uniform (~20% difference), there was greater variability amongst cDMF-B and cFumaderm capsules (> 30% difference). Impurity testing revealed 2 and 4 unknown components within cDMF-A and cDMF-B, respectively, with levels ranging from 0.05 to 0.81% of total drug content. In in vitro testing of cDMF-A,>10% (12 mg) of DMF was released after 120 min in simulated gastric fluid and 17% (20 mg) released in simulated intestinal fluid after 60 min. While minimal amount of DMF was released from cDMF-B in simulated gastric fluid, 50% (60 mg) of DMF was released after 60 min in simulated intestinal fluid. Similarly for cFumaderm, a fraction (< 20 mg) of the 120 mg target dose was released after several hours in simulated intestinal fluid. The uniformity of release rates across capsules varied significantly.

Conclusion: These results demonstrate that compounded fumarates are not equivalent to licensed products and may present unknown safety, efficacy, or quality risks.

Supporting Information

 
  • References

  • 1 Luessi F, Siffrin V, Zipp F. Expert Rev Neurother 2012; 12: 1061-1076
  • 2 Gold R, Kappos L, Arnold DL et al. N Engl J Med 2012; 367: 1098-1107
  • 3 Fox RJ, Miller DH, Phillips JT et al. N Engl J Med 2012; 367: 1087-1097
  • 4 Meissner M, Valesky EM, Kippenberger S et al. J Dtsch Dermatol Ges 2012; 10: 793-801
  • 5 Barenberg BJ, Smith T, Nihira MA. J Org Chem 2014; 107: 155-156
  • 6 Food and Drug Administration (FDA) Available at: Food and Drug Administration (FDA.gov). Last update 2011
  • 7 US Pharmacopeial Convention . United States Pharmacopeia 37 – National Formulary 32. 2015
  • 8 The European Pharmacopoeia Commission . European Pharmacopoeia. 8th Edition 13 A.D
  • 9 Halpern R, Agarwal S, Dembek C et al. Patient Prefer Adherence 2011; 5: 73-84
  • 10 Available at: Govtrack.us. Last update 2013